(Q80356257)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

author name string

Yanfang Li

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Kevin W Finkel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Wei Hu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Jihong Liu

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

Robert Coleman

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

John J Kavanagh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

publication date

18 May 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

volume

106

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

page(s)

375-380

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

Systemic anticancer therapy in gynecological cancer patients with renal dysfunction.

30 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: a retrospective comparative study of single-agent dosages.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Prediction of creatinine clearance from serum creatinine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Re: new guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Liposomal anthracycline treatment for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Evaluation of pegylated liposomal doxorubicin (Doxil) as second-line chemotherapy of squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

A randomised phase II study of two different schedules of pegylated liposomal doxorubicin in metastatic breast cancer (EORTC-10993).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Cardiac safety of liposomal anthracyclines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

Cardiac safety profile of prolonged (>or=6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.04.011

10.1016/J.YGYNO.2007.04.011

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17512575%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference